Digestive Disease Week® 2021 to Showcase the TissueCypher® Barrett’s Esophagus Assay as a Paradigm-shifting Precision Medicine Tool
Mayo Clinic and AMC Amsterdam to Present Data on Predicting Progression to Esophageal Cancer in Barrett’s Esophagus
May 17, 2021 08:38 ET | Source: Cernostics Cernostics Pittsburgh, Pennsylvania, UNITED STATES
PITTSBURGH, Pennsylvania, May 17, 2021 – Cernostics (
cernostics.com/) a pioneer in delivering spatialomics to the clinic, announced today that new results from clinical studies on the TissueCypher® Barrett’s Esophagus Assay will be presented at Digestive Disease Week® (DDW®) 2021 taking place May 21-23.
Clinical studies by Mayo Clinic, and Academic Medical Center in The Netherlands, two of the world’s leading academic institutions in the area of diagnosis and treatment of Barrett’s esophagus (BE) and esophageal cancer prevention, will be presented during the oral lecture se
Aqua Medical Announces First-in-Human Experience of RF Vapor Ablation Therapy for Barrett s Esophagus Published in Endoscopy Entrepreneur and Venture Capitalist William N. (Bill) Starling Joins Board of Directors with Board Advisor Pete Nicholas (Founder of Boston Scientific) and Director Greg Barrett
March 11, 2021 11:00 ET | Source: Aqua Medical Aqua Medical Santa Ana, California, UNITED STATES
Santa Ana, CA, March 11, 2021 (GLOBE NEWSWIRE) Aqua Medical, developer of the FDA 510(k)-cleared vapor-based endoscopic ablation technology for gastrointestinal disease and GI cancer prevention, today announced that clinical results from the first-in-human experience of its RF Vapor Ablation (RFVA) therapy for Barrett s esophagus (BE) were published in Endoscopy.